2006
DOI: 10.1016/j.ijcard.2005.02.016
|View full text |Cite
|
Sign up to set email alerts
|

Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

7
64
0
2

Year Published

2007
2007
2023
2023

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 120 publications
(73 citation statements)
references
References 32 publications
7
64
0
2
Order By: Relevance
“…In the above-referenced human study (30), diabetic patients who had elevated iAng II levels were on ACE-inhibitor therapy. In the latter case, a rise in Ang II levels could be attributed to an "ACE-escape" phenomenon, which is believed to occur after prolonged treatment with ACE inhibitors (34). In the present study, the lack of reduction in iAng II levels after only 1 week of ACE-inhibitor treatment strongly suggests an ACE-independent mechanism of iAng II synthesis, corroborating in vitro observations.…”
Section: Discussionsupporting
confidence: 87%
“…In the above-referenced human study (30), diabetic patients who had elevated iAng II levels were on ACE-inhibitor therapy. In the latter case, a rise in Ang II levels could be attributed to an "ACE-escape" phenomenon, which is believed to occur after prolonged treatment with ACE inhibitors (34). In the present study, the lack of reduction in iAng II levels after only 1 week of ACE-inhibitor treatment strongly suggests an ACE-independent mechanism of iAng II synthesis, corroborating in vitro observations.…”
Section: Discussionsupporting
confidence: 87%
“…Moreover, cardiac remodelling occurs in response to activation of the reninangiotensin-aldosterone system. It has been reported that the plasma Ang II concentration is higher in patients with CHF compared to healthy subjects (16). The present study demonstrated that the plasma Ang II level increased gradually dependent on the severity of heart failure.…”
Section: Discussionsupporting
confidence: 69%
“…As a first step toward understanding the mechanisms that mediate the adverse vascular effects of aldosterone, we began by exploring the effect of aldosterone in the mouse wire carotid injury model, a reproducible method to study these specific responses to endothelial injury (27)(28)(29)(30)(31)(32). Aldosterone was infused at a dose that increased circulating aldosterone concentrations to levels consistent with what is found in patients with heart failure and atherosclerosis (33,34) without altering systolic blood pressure or animal weight (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI40205DS1). Vascular injury resulted in increased medial SMC proliferation, which was significantly augmented by low-dose aldosterone infusion (Supplemental Figure 1A).…”
Section: Resultsmentioning
confidence: 99%